Literature DB >> 20086112

Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men.

Joke Beuten1, Jonathan A L Gelfond, Jennifer L Franke, Stacey Shook, Teresa L Johnson-Pais, Ian M Thompson, Robin J Leach.   

Abstract

Three genes, namely, ELAC2 (HPC2 locus) on chromosome 17p11, 2'-5'-oligoisoadenlyate-synthetase-dependent ribonuclease L (RNASEL, HPC1 locus), and macrophage scavenger receptor 1 (MSR1) within a region of linkage on chromosome 8p, have been identified as hereditary tumor suppressor genes in prostate cancer. We genotyped 41 tagged single nucleotide polymorphisms (SNPs) covering the three genes in a case-control cohort, which included 1,436 Caucasians, 648 Hispanics, and 270 African Americans. SNPs within MSR1, ELAC2, and RNASEL were significantly associated with risk of prostate cancer albeit with differences among the three ethnic groups (P = 0.043-1.0 x 10(-5)). In Caucasians, variants within MSR1 and ELAC2 are most likely to confer prostate cancer risk, and rs11545302 (ELAC2) showed a main effect independent of other significant SNPs (P = 2.03 x 10(-5)). A major haplotype G-A-C-G-C-G combining five SNPs within MSR1 was further shown to increase prostate cancer risk significantly in this study group. Variants in RNASEL had the strongest effects on prostate cancer risk estimates in Hispanics and also showed an interaction effect of family history. In African Americans, single SNPs within MSR1 were significantly associated with prostate cancer risk. A major risk haplotype C-G-G-C-G of five SNPs within ELAC2 was found in this group. Combining high-risk genotypes of MSR1 and ELAC2 in Caucasians and of RNASEL and MSR1 in Hispanics showed synergistic effects and suggest that an interaction between both genes in each ethnicity is likely to confer prostate cancer risk. Our findings corroborate the involvement of ELAC2, MSR1, and RNASEL in the etiology of prostate cancer even in individuals without a family history.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20086112      PMCID: PMC5034730          DOI: 10.1158/1055-9965.EPI-09-0864

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  53 in total

Review 1.  Familial prostate cancer.

Authors:  J L Stanford; E A Ostrander
Journal:  Epidemiol Rev       Date:  2001       Impact factor: 6.222

2.  Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma.

Authors:  Ferrin C Noonan-Wheeler; William Wu; Kimberly A Roehl; Aleksandra Klim; John Haugen; Brian K Suarez; Adam S Kibel
Journal:  Prostate       Date:  2006-01-01       Impact factor: 4.104

Review 3.  Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral response.

Authors:  Robert H Silverman
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

4.  Two putative tumor suppressor genes on chromosome arm 8p may play different roles in prostate cancer.

Authors:  K Oba; H Matsuyama; S Yoshihiro; F Kishi; M Takahashi; M Tsukamoto; M Kinjo; K Sagiyama; K Naito
Journal:  Cancer Genet Cytogenet       Date:  2001-01-01

5.  Mendelian inheritance of familial prostate cancer.

Authors:  B S Carter; T H Beaty; G D Steinberg; B Childs; P C Walsh
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

6.  Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men.

Authors:  Hanna Rennert; Charnita M Zeigler-Johnson; Kathakali Addya; Matthew J Finley; Amy H Walker; Elaine Spangler; Debra G B Leonard; Alan Wein; S Bruce Malkowicz; Timothy R Rebbeck
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-04       Impact factor: 4.254

Review 7.  Inflammation, infection, and prostate cancer.

Authors:  Eric A Klein; Robert Silverman
Journal:  Curr Opin Urol       Date:  2008-05       Impact factor: 2.309

8.  Prevalence, treatment modalities and prognosis of familial prostate cancer in a screened population.

Authors:  Stijn Roemeling; Monique J Roobol; Stijn H de Vries; Claartje Gosselaar; Theo H van der Kwast; Fritz H Schröder
Journal:  J Urol       Date:  2006-04       Impact factor: 7.450

Review 9.  Chromosomal deletions and tumor suppressor genes in prostate cancer.

Authors:  J T Dong
Journal:  Cancer Metastasis Rev       Date:  2001       Impact factor: 9.264

10.  Multiple loci identified in a genome-wide association study of prostate cancer.

Authors:  Gilles Thomas; Kevin B Jacobs; Meredith Yeager; Peter Kraft; Sholom Wacholder; Nick Orr; Kai Yu; Nilanjan Chatterjee; Robert Welch; Amy Hutchinson; Andrew Crenshaw; Geraldine Cancel-Tassin; Brian J Staats; Zhaoming Wang; Jesus Gonzalez-Bosquet; Jun Fang; Xiang Deng; Sonja I Berndt; Eugenia E Calle; Heather Spencer Feigelson; Michael J Thun; Carmen Rodriguez; Demetrius Albanes; Jarmo Virtamo; Stephanie Weinstein; Fredrick R Schumacher; Edward Giovannucci; Walter C Willett; Olivier Cussenot; Antoine Valeri; Gerald L Andriole; E David Crawford; Margaret Tucker; Daniela S Gerhard; Joseph F Fraumeni; Robert Hoover; Richard B Hayes; David J Hunter; Stephen J Chanock
Journal:  Nat Genet       Date:  2008-02-10       Impact factor: 38.330

View more
  23 in total

1.  An update analysis of two polymorphisms in encoding ribonuclease L gene and prostate cancer risk: involving 13,372 cases and 11,953 controls.

Authors:  Yuan-Yuan Mi; Li-Jie Zhu; Sheng Wu; Ning-Han Feng
Journal:  Genes Nutr       Date:  2011-04-17       Impact factor: 5.523

2.  RNASEL Asp541Glu and Arg462Gln polymorphisms in prostate cancer risk: evidences from a meta-analysis.

Authors:  Bingbing Wei; Zhuoqun Xu; Jun Ruan; Ming Zhu; Ke Jin; Deqi Zhou; Zhiqiang Yan; Feng Xuan; Hongyi Zhou; Xing Huang; Jian Zhang; Peng Lu; Jianfeng Shao
Journal:  Mol Biol Rep       Date:  2011-06-09       Impact factor: 2.316

3.  Identification of genetic risk associated with prostate cancer using ancestry informative markers.

Authors:  L J Ricks-Santi; V Apprey; T Mason; B Wilson; M Abbas; W Hernandez; S Hooker; M Doura; G Bonney; G Dunston; R Kittles; C Ahaghotu
Journal:  Prostate Cancer Prostatic Dis       Date:  2012-07-17       Impact factor: 5.554

4.  Genetic variation in RNASEL associated with prostate cancer risk and progression.

Authors:  Mara S Meyer; Kathryn L Penney; Jennifer R Stark; Fredrick R Schumacher; Howard D Sesso; Massimo Loda; Michelangelo Fiorentino; Stephen Finn; Richard J Flavin; Tobias Kurth; Alkes L Price; Edward L Giovannucci; Katja Fall; Meir J Stampfer; Jing Ma; Lorelei A Mucci
Journal:  Carcinogenesis       Date:  2010-06-24       Impact factor: 4.944

Review 5.  The link between benign prostatic hyperplasia and prostate cancer.

Authors:  David D Ørsted; Stig E Bojesen
Journal:  Nat Rev Urol       Date:  2012-11-20       Impact factor: 14.432

6.  RNASEL -1385G/A polymorphism and cancer risk: a meta-analysis based on 21 case-control studies.

Authors:  Li-Feng Zhang; Yuan-Yuan Mi; Chao Qin; Yong Wang; Qiang Cao; Jun-Feng Wei; Yao-Jun Zhou; Ning-Han Feng; Wei Zhang
Journal:  Mol Biol Rep       Date:  2011-01-09       Impact factor: 2.316

7.  8p deletion is strongly linked to poor prognosis in breast cancer.

Authors:  P Lebok; A Mittenzwei; M Kluth; C Özden; B Taskin; K Hussein; K Möller; A Hartmann; A Lebeau; I Witzel; S Mahner; L Wölber; F Jänicke; S Geist; P Paluchowski; C Wilke; U Heilenkötter; R Simon; G Sauter; L Terracciano; R Krech; A von der Assen; V Müller; E Burandt
Journal:  Cancer Biol Ther       Date:  2015-05-11       Impact factor: 4.742

8.  Suppression of antigen-specific CD4+ T cell activation by SRA/CD204 through reducing the immunostimulatory capability of antigen-presenting cell.

Authors:  Huanfa Yi; Daming Zuo; Xiaofei Yu; Fanlei Hu; Masoud H Manjili; Zhengliang Chen; John R Subjeck; Xiang-Yang Wang
Journal:  J Mol Med (Berl)       Date:  2011-11-15       Impact factor: 4.599

9.  SIGLEC12, a human-specific segregating (pseudo)gene, encodes a signaling molecule expressed in prostate carcinomas.

Authors:  Nivedita Mitra; Kalyan Banda; Tasha K Altheide; Lana Schaffer; Teresa L Johnson-Pais; Joke Beuten; Robin J Leach; Takashi Angata; Nissi Varki; Ajit Varki
Journal:  J Biol Chem       Date:  2011-05-09       Impact factor: 5.157

10.  Arg462Gln and Asp541Glu polymorphisms in ribonuclease L and prostate cancer risk: a meta-analysis.

Authors:  Yuanyuan Mi; Qianqian Yu; Zhichao Min; Bin Xu; Lifeng Zhang; Wei Zhang; Ninghan Feng; Lixin Hua
Journal:  J Biomed Res       Date:  2010-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.